Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 2, Series 5
January 30, 2026 - - Podcast -
International HTA Collaboration continues as global pricing pressures evolve
January 29, 2026 - - Latest News -
How an Australian Campaign Is tackling the silent epidemic of heart and kidney disease
January 29, 2026 - - Latest News -
ARCS warns workforce gaps threaten returns on clinical trials reform
January 29, 2026 - - Latest News -
AstraZeneca appoints new country president as Ben McDonald transitions to global role
January 29, 2026 - - Latest News -
Why do some appear so uncomfortable with this group of people getting help?
January 29, 2026 - - Latest News -
New digital health reforms to give Australians a more complete medicines history
January 28, 2026 - - Latest News